Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS).

Baraliakos X, Østergaard M, Gensler LS, Poddubnyy D, Lee EY, Kiltz U, Martin R, Sawata H, Readie A, Porter B; SURPASS Study Group.

Clin Drug Investig. 2020 Mar;40(3):269-278. doi: 10.1007/s40261-020-00886-7.

PMID:
31983056
2.

Response to: 'Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?' by Wallman et al.

Proft F, Protopopov M, Rios Rodriguez V, Torgutalp M, Siegmund B, Poddubnyy D.

Ann Rheum Dis. 2019 Dec 9. pii: annrheumdis-2019-216735. doi: 10.1136/annrheumdis-2019-216735. [Epub ahead of print] No abstract available.

PMID:
31818807
3.

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.

Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Østergaard M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, Hojnik M, Gallo G, Li X, Adams D, Carlier H, Sieper J; COAST-X Study Group.

Lancet. 2020 Jan 4;395(10217):53-64. doi: 10.1016/S0140-6736(19)32971-X. Epub 2019 Dec 5.

PMID:
31813637
4.

Balancing benefits and risks in the era of biologics.

Adami G, Saag KG, Chapurlat RD, Guañabens N, Haugeberg G, Lems WF, Matijevic R, Peel N, Poddubnyy D, Geusens P.

Ther Adv Musculoskelet Dis. 2019 Oct 24;11:1759720X19883973. doi: 10.1177/1759720X19883973. eCollection 2019. Review.

5.

Should we combine biologics with methotrexate in axial spondyloarthritis?

Poddubnyy D, Amital H, Rubbert-Roth A.

Autoimmun Rev. 2019 Dec;18(12):102402. doi: 10.1016/j.autrev.2019.102402. Epub 2019 Oct 24. Review. No abstract available.

PMID:
31669544
6.

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.

Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, Van den Bosch F, Delicha EM, Talloczy Z, Fierlinger A.

RMD Open. 2019 Sep 3;5(2):e001005. doi: 10.1136/rmdopen-2019-001005. eCollection 2019.

7.

The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis.

Sieper J, Poddubnyy D, Miossec P.

Nat Rev Rheumatol. 2019 Dec;15(12):747-757. doi: 10.1038/s41584-019-0294-7. Epub 2019 Sep 24. Review.

PMID:
31551538
8.

[Pathogenesis of spondylarthritis : Relevance for treatment].

Sieper J, Poddubnyy D.

Z Rheumatol. 2020 Feb;79(1):5-12. doi: 10.1007/s00393-019-00708-y. Review. German.

PMID:
31506791
9.

Emerging drugs for the treatment of noninfectious uveitis.

Pleyer U, Pohlmann D, Kardeş E, Poddubnyy D, Rademacher J.

Expert Opin Emerg Drugs. 2019 Sep;24(3):173-190. doi: 10.1080/14728214.2019.1663823. Epub 2019 Sep 19.

PMID:
31498689
10.

MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group.

Maksymowych WP, Lambert RG, Østergaard M, Pedersen SJ, Machado PM, Weber U, Bennett AN, Braun J, Burgos-Vargas R, de Hooge M, Deodhar AA, Eshed I, Jurik AG, Hermann KA, Landewé RB, Marzo-Ortega H, Navarro-Compán V, Poddubnyy D, Reijnierse M, Rudwaleit M, Sieper J, Van den Bosch FE, van der Heijde D, van der Horst-Bruinsma IE, Wichuk S, Baraliakos X.

Ann Rheum Dis. 2019 Nov;78(11):1550-1558. doi: 10.1136/annrheumdis-2019-215589. Epub 2019 Aug 17.

PMID:
31422357
11.

Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis.

Proft F, Muche B, Spiller L, Rios Rodriguez V, Rademacher J, Weber AK, Lüders S, Protopopov M, Redeker I, Spiller I, Sieper J, Poddubnyy D.

Joint Bone Spine. 2020 Jan;87(1):69-73. doi: 10.1016/j.jbspin.2019.07.007. Epub 2019 Jul 29.

12.

Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts.

Boel A, Molto A, van der Heijde D, Ciurea A, Dougados M, Gensler LS, Santos MJ, De Miguel E, Poddubnyy D, Rudwaleit M, van Tubergen A, van Gaalen FA, Ramiro S.

Ann Rheum Dis. 2019 Nov;78(11):1545-1549. doi: 10.1136/annrheumdis-2019-215707. Epub 2019 Jul 30.

13.

[Cost of illness in axial spondylarthritis for patients with and without tumor necrosis factor inhibitor treatment: results of a routine data analysis].

Redeker I, Callhoff J, Hoffmann F, Saam J, Haibel H, Sieper J, Zink A, Poddubnyy D.

Z Rheumatol. 2020 Feb;79(1):85-94. doi: 10.1007/s00393-019-0678-8. German.

PMID:
31359143
14.

Reality of care for musculoskeletal diseases at the population level : Results of the PROCLAIR collaborative project.

Callhoff J, Albrecht K, Hoffmann F, Poddubnyy D, Günther KP, Zink A.

Z Rheumatol. 2019 Dec;78(Suppl 2):73-79. doi: 10.1007/s00393-019-0669-9. Review.

PMID:
31342161
15.

Current Unmet Needs in Spondyloarthritis.

Poddubnyy D, Sieper J.

Curr Rheumatol Rep. 2019 Jul 13;21(9):43. doi: 10.1007/s11926-019-0844-7. Review.

PMID:
31302784
16.

[Reality of care for musculoskeletal diseases at the population level : Results of the PROCLAIR collaborative project. German version].

Callhoff J, Albrecht K, Hoffmann F, Poddubnyy D, Günther KP, Zink A.

Z Rheumatol. 2019 Oct;78(8):713-721. doi: 10.1007/s00393-019-0664-1. Review. German.

PMID:
31273459
17.

Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison.

Braun J, Haibel H, de Hooge M, Landewé R, Rudwaleit M, Fox T, Readie A, Richards HB, Porter B, Martin R, Poddubnyy D, Sieper J, van der Heijde D.

Arthritis Res Ther. 2019 Jun 7;21(1):142. doi: 10.1186/s13075-019-1911-1.

18.

[Health care and disease burden in persons with axial spondyloarthritis in Germany].

Haibel H, Redeker I, Zink A, Callhoff J, Marschall U, Hoffmann F, Sieper J, Poddubnyy D.

Z Rheumatol. 2019 Nov;78(9):865-874. doi: 10.1007/s00393-019-0650-7. German.

PMID:
31172266
19.

Emerging treatment options for spondyloarthritis.

Torgutalp M, Poddubnyy D.

Best Pract Res Clin Rheumatol. 2018 Jun;32(3):472-484. doi: 10.1016/j.berh.2019.01.014. Epub 2019 Feb 21. Review.

PMID:
31171316
20.

Recent advances in spondyloarthritis.

Poddubnyy D, Haroon N.

Best Pract Res Clin Rheumatol. 2018 Jun;32(3):329-330. doi: 10.1016/j.berh.2019.03.014. Epub 2019 Apr 13. No abstract available.

PMID:
31171305
21.

Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis.

Llop M, Rios Rodriguez V, Redeker I, Sieper J, Haibel H, Rudwaleit M, Poddubnyy D.

Arthritis Res Ther. 2019 May 24;21(1):126. doi: 10.1186/s13075-019-1913-z.

22.

Correction: HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort.

de Winter JJ, Blijdorp IC, de Jong HM, Sauter J, Schmidt AH, van Gaalen FA, van der Heijde D, Poddubnyy D, Yeremenko NG, van de Sande MG, Baeten DL.

Genes Immun. 2019 Nov;20(8):690. doi: 10.1038/s41435-019-0076-x.

PMID:
31068685
23.

IL-17 inhibition in axial spondyloarthritis: current and future perspectives.

Torgutalp M, Poddubnyy D.

Expert Opin Biol Ther. 2019 Jul;19(7):631-641. doi: 10.1080/14712598.2019.1605352. Epub 2019 Apr 19.

PMID:
30957574
24.

Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data.

Redeker I, Callhoff J, Hoffmann F, Haibel H, Sieper J, Zink A, Poddubnyy D.

Rheumatology (Oxford). 2019 Sep 1;58(9):1634-1638. doi: 10.1093/rheumatology/kez090.

PMID:
30903141
25.

The European Map of Axial Spondyloarthritis: Capturing the Patient Perspective-an Analysis of 2846 Patients Across 13 Countries.

Garrido-Cumbrera M, Poddubnyy D, Gossec L, Gálvez-Ruiz D, Bundy C, Mahapatra R, Makri S, Christen L, Delgado-Domínguez CJ, Sanz-Gómez S, Plazuelo-Ramos P, Navarro-Compán V; EMAS Working Group.

Curr Rheumatol Rep. 2019 Mar 12;21(5):19. doi: 10.1007/s11926-019-0819-8. Review.

26.

Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis.

Rademacher J, Tietz LM, Le L, Hartl A, Hermann KA, Sieper J, Mansmann U, Rudwaleit M, Poddubnyy D.

Rheumatology (Oxford). 2019 Sep 1;58(9):1556-1564. doi: 10.1093/rheumatology/kez025.

PMID:
30830164
27.

HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort.

de Winter JJ, Blijdorp IC, de Jong HM, Sauter J, Schmidt AH, van Gaalen FA, van der Heijde D, Poddubnyy D, Yeremenko NG, van de Sande MG, Baeten DL.

Genes Immun. 2019 Nov;20(8):671-677. doi: 10.1038/s41435-019-0061-4. Epub 2019 Feb 26. Erratum in: Genes Immun. 2019 May 9;:.

PMID:
30809016
28.

Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care.

Poddubnyy D, Callhoff J, Spiller I, Listing J, Braun J, Sieper J, Rudwaleit M.

RMD Open. 2018 Dec 5;4(2):e000825. doi: 10.1136/rmdopen-2018-000825. eCollection 2018.

29.

Detection of Sacroiliitis by Short-tau Inversion Recovery and T2-weighted Turbo Spin Echo Sequences: Results from the SIMACT Study.

Greese J, Diekhoff T, Sieper J, Schwenke C, Makowski MR, Poddubnyy D, Hamm B, Hermann KGA.

J Rheumatol. 2019 Apr;46(4):376-383. doi: 10.3899/jrheum.171425. Epub 2019 Jan 15.

PMID:
30647167
30.

Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Long-Term Anti-Tumor Necrosis Factor Treatment: Six-Year Results of Continuous Treatment With Etanercept.

Rios Rodriguez V, Hermann KG, Weiß A, Listing J, Haibel H, Althoff C, Proft F, Behmer O, Sieper J, Poddubnyy D.

Arthritis Rheumatol. 2019 May;71(5):722-728. doi: 10.1002/art.40786. Epub 2019 Mar 7.

PMID:
30625261
31.

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.

Braun J, Baraliakos X, Deodhar A, Poddubnyy D, Emery P, Delicha EM, Talloczy Z, Porter B.

Rheumatology (Oxford). 2019 May 1;58(5):859-868. doi: 10.1093/rheumatology/key375.

32.

Susceptibility-weighted MR imaging to improve the specificity of erosion detection: a prospective feasibility study in hand arthritis.

Ulas ST, Diekhoff T, Hermann KGA, Poddubnyy D, Hamm B, Makowski MR.

Skeletal Radiol. 2019 May;48(5):721-728. doi: 10.1007/s00256-018-3116-0. Epub 2018 Dec 18.

PMID:
30564856
33.

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.

Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, Järvinen P, Sanchez-Burson J, Gaffney K, Lee EB, Krishnan E, Santisteban S, Li X, Zhao F, Carlier H, Reveille JD; COAST-W Study Group.

Arthritis Rheumatol. 2019 Apr;71(4):599-611. doi: 10.1002/art.40753. Epub 2019 Mar 8.

34.

Ultra-low-dose CT detects synovitis in patients with suspected rheumatoid arthritis.

Diekhoff T, Ulas ST, Poddubnyy D, Schneider U, Hermann S, Biesen R, Burmester GR, Hamm B, Hermann KG.

Ann Rheum Dis. 2019 Jan;78(1):31-35. doi: 10.1136/annrheumdis-2018-213904. Epub 2018 Sep 29.

35.

An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus.

Schulte-Wrede U, Sörensen T, Grün JR, Häupl T, Hirseland H, Steinbrich-Zöllner M, Wu P, Radbruch A, Poddubnyy D, Sieper J, Syrbe U, Grützkau A.

Arthritis Res Ther. 2018 Aug 29;20(1):191. doi: 10.1186/s13075-018-1692-y.

36.

Improved detection of erosions in the sacroiliac joints on MRI with volumetric interpolated breath-hold examination (VIBE): results from the SIMACT study.

Diekhoff T, Greese J, Sieper J, Poddubnyy D, Hamm B, Hermann KA.

Ann Rheum Dis. 2018 Nov;77(11):1585-1589. doi: 10.1136/annrheumdis-2018-213393. Epub 2018 Aug 10.

PMID:
30097454
37.

[Advances in research on axial spondyloarthritis].

Rademacher J, Poddubnyy D.

Z Rheumatol. 2018 Sep;77(7):609-612. doi: 10.1007/s00393-018-0517-3. German. No abstract available.

PMID:
30069739
38.

Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria.

Proft F, Poddubnyy D.

Ther Adv Musculoskelet Dis. 2018 Jun;10(5-6):129-139. doi: 10.1177/1759720X18773726. Epub 2018 May 17. Review.

39.

Response to 'Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier' by Alunno et al.

Redeker I, Hoffmann F, Callhoff J, Haibel H, Sieper J, Zink A, Poddubnyy D.

Ann Rheum Dis. 2019 Jun;78(6):e55. doi: 10.1136/annrheumdis-2018-213620. Epub 2018 May 31. No abstract available.

PMID:
29853451
40.

Radiographic progression in non-radiographic axial spondyloarthritis.

Protopopov M, Poddubnyy D.

Expert Rev Clin Immunol. 2018 Jun;14(6):525-533. doi: 10.1080/1744666X.2018.1477591. Epub 2018 May 24. Review.

PMID:
29774755
41.

[Biomarkers and imaging for diagnosis and stratification of rheumatoid arthritis and spondylarthritis in the BMBF consortium ArthroMark].

Häupl T, Skapenko A, Hoppe B, Skriner K, Burkhardt H, Poddubnyy D, Ohrndorf S, Sewerin P, Mansmann U, Stuhlmüller B, Schulze-Koops H, Burmester GR.

Z Rheumatol. 2018 May;77(Suppl 1):16-23. doi: 10.1007/s00393-018-0458-x. Review. German.

PMID:
29691690
42.

Restless legs syndrome is a relevant comorbidity in patients with inflammatory bowel disease.

Becker J, Berger F, Schindlbeck KA, Poddubnyy D, Koch PM, Preiß JC, Siegmund B, Marzinzik F, Maul J.

Int J Colorectal Dis. 2018 Jul;33(7):955-962. doi: 10.1007/s00384-018-3032-8. Epub 2018 Apr 3.

PMID:
29610943
43.

Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity.

Schwedler C, Häupl T, Kalus U, Blanchard V, Burmester GR, Poddubnyy D, Hoppe B.

Arthritis Res Ther. 2018 Mar 14;20(1):44. doi: 10.1186/s13075-018-1540-0.

44.

Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data.

Redeker I, Hoffmann F, Callhoff J, Haibel H, Sieper J, Zink A, Poddubnyy D.

Ann Rheum Dis. 2018 Jul;77(7):1017-1024. doi: 10.1136/annrheumdis-2017-212629. Epub 2018 Mar 10.

45.

Emerging drugs for the treatment of axial spondyloarthritis.

Rademacher J, Poddubnyy D.

Expert Opin Emerg Drugs. 2018 Mar;23(1):83-96. doi: 10.1080/14728214.2018.1445719. Epub 2018 Mar 1. Review.

PMID:
29475394
46.

Challenges and Advances in Targeting Remission in Axial Spondyloarthritis.

Baraliakos X, Berenbaum F, Favalli EG, Olivieri I, Ostendorf B, Poddubnyy D, DE Vlam K.

J Rheumatol. 2018 Feb;45(2):153-157. doi: 10.3899/jrheum.170222. No abstract available.

47.

Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort.

Poddubnyy D, Listing J, Haibel H, Knüppel S, Rudwaleit M, Sieper J.

Rheumatology (Oxford). 2018 Apr 1;57(4):703-711. doi: 10.1093/rheumatology/kex475.

PMID:
29373733
48.

Hematopoietic and mesenchymal stem cells: a promising new therapy for spondyloarthritis?

Rios Rodriguez V, Llop M, Poddubnyy D.

Immunotherapy. 2017 Sep;9(11):899-911. doi: 10.2217/imt-2017-0034. Review.

PMID:
29338611
49.

Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort.

Protopopov M, Sieper J, Haibel H, Listing J, Rudwaleit M, Poddubnyy D.

Arthritis Res Ther. 2017 Oct 24;19(1):240. doi: 10.1186/s13075-017-1453-3.

50.

What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?

Poddubnyy D, Sieper J.

Rheumatology (Oxford). 2018 Jul 1;57(7):1145-1150. doi: 10.1093/rheumatology/kex361.

PMID:
29040753

Supplemental Content

Loading ...
Support Center